Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Debt / NOTE 4.500% 7/1
-
Market price (% of par)
-
124.85%
-
Total 13F principal
-
$52,604,000
-
Principal change
-
-$610,000
-
Total reported market value
-
$65,197,000
-
Number of holders
-
11
-
Value change
-
+$105,815
-
Number of buys
-
5
-
Number of sells
-
6
Institutional Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q3 2016
As of 30 Sep 2016,
MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 was held by
11 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$52,604,000
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, JPMORGAN CHASE & CO, Polygon Management Ltd., Polar Capital LLP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, PUTNAM INVESTMENTS LLC, AMERIPRISE FINANCIAL INC, Tekla Capital Management LLC, and PALISADE CAPITAL MANAGEMENT LLC/NJ.
This page lists
11
institutional bondholders reporting positions
for the Q3 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.